Mina Kelleni

1.0k total citations
33 papers, 434 citations indexed

About

Mina Kelleni is a scholar working on Infectious Diseases, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mina Kelleni has authored 33 papers receiving a total of 434 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 6 papers in Molecular Biology and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mina Kelleni's work include COVID-19 Clinical Research Studies (11 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Liver Disease Diagnosis and Treatment (4 papers). Mina Kelleni is often cited by papers focused on COVID-19 Clinical Research Studies (11 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Liver Disease Diagnosis and Treatment (4 papers). Mina Kelleni collaborates with scholars based in Egypt, Saudi Arabia and Spain. Mina Kelleni's co-authors include Aly M. Abdelrahman, Mohamed Ibrahim, Ayman Geddawy, Entesar F. Amin, Salwa A. Ibrahim, Farooq Ahmed Wani, Mahrous A. Ibrahim, Alaa A. Mohamed and Wafaey Gomaa and has published in prestigious journals such as Life Sciences, European Journal of Pharmacology and Biomedicine & Pharmacotherapy.

In The Last Decade

Mina Kelleni

26 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mina Kelleni Egypt 10 118 109 100 59 56 33 434
Onkar Bedi India 14 184 1.6× 56 0.5× 144 1.4× 38 0.6× 30 0.5× 25 626
Mohamed N. Amin Egypt 14 198 1.7× 167 1.5× 57 0.6× 24 0.4× 99 1.8× 31 654
Afagh Garjani Iran 13 172 1.5× 51 0.5× 45 0.5× 160 2.7× 51 0.9× 42 517
Shukui Wang China 10 185 1.6× 156 1.4× 57 0.6× 18 0.3× 46 0.8× 19 676
Hongwei Shi China 9 114 1.0× 52 0.5× 29 0.3× 23 0.4× 16 0.3× 37 339
Michel Guillaume Belgium 14 80 0.7× 29 0.3× 74 0.7× 12 0.2× 66 1.2× 28 657
Neelam Malik India 17 143 1.2× 93 0.9× 46 0.5× 26 0.4× 28 0.5× 63 767
Qianzhou Lv China 13 112 0.9× 56 0.5× 94 0.9× 18 0.3× 12 0.2× 41 428
Sanlan Wu China 14 139 1.2× 194 1.8× 89 0.9× 26 0.4× 69 1.2× 37 538
Xiaoxia Qiu China 15 198 1.7× 24 0.2× 62 0.6× 26 0.4× 15 0.3× 48 605

Countries citing papers authored by Mina Kelleni

Since Specialization
Citations

This map shows the geographic impact of Mina Kelleni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mina Kelleni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mina Kelleni more than expected).

Fields of papers citing papers by Mina Kelleni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mina Kelleni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mina Kelleni. The network helps show where Mina Kelleni may publish in the future.

Co-authorship network of co-authors of Mina Kelleni

This figure shows the co-authorship network connecting the top 25 collaborators of Mina Kelleni. A scholar is included among the top collaborators of Mina Kelleni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mina Kelleni. Mina Kelleni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Kelleni, Mina. (2024). COVID-19 mortality paradox (United States vs Africa): Mass vaccination vs early treatment. PubMed. 14(1). 88674–88674. 2 indexed citations
4.
5.
Kelleni, Mina. (2023). The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one. Inflammopharmacology. 31(6). 3335–3338. 6 indexed citations
6.
Ibrahim, Mahrous A., et al.. (2021). Resveratrol protects against cisplatin-induced ovarian and uterine toxicity in female rats by attenuating oxidative stress, inflammation and apoptosis. Chemico-Biological Interactions. 338. 109402–109402. 59 indexed citations
7.
Kelleni, Mina. (2021). Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy. Biomedicine & Pharmacotherapy. 139. 111626–111626. 23 indexed citations
8.
9.
Kelleni, Mina. (2021). NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Review of Anti-infective Therapy. 20(1). 17–21. 19 indexed citations
10.
Kelleni, Mina. (2020). Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomedicine & Pharmacotherapy. 133. 110982–110982. 73 indexed citations
11.
Kelleni, Mina. (2020). ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. Inflammopharmacology. 28(6). 1477–1480. 14 indexed citations
12.
13.
14.
Kelleni, Mina, Salwa A. Ibrahim, & Aly M. Abdelrahman. (2016). Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats: impact of oxidative stress, inflammation and apoptosis. Toxicology Mechanisms and Methods. 26(5). 371–377. 35 indexed citations
15.
16.
17.
Kelleni, Mina. (2015). Fludarabine Monotherapy Fails to Control a Case of Relapsing Non-HodgkinâÂÂs Lymphoma. General Medicine Open Access. 3(4). 1 indexed citations
18.
Kelleni, Mina, Entesar F. Amin, & Aly M. Abdelrahman. (2015). Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and Apoptosis. Journal of Toxicology. 2015. 1–8. 64 indexed citations
19.
Ibrahim, Mohamed, Mina Kelleni, & Ayman Geddawy. (2012). Nonalcoholic fatty liver disease: Current and potential therapies. Life Sciences. 92(2). 114–118. 65 indexed citations
20.
Ibrahim, Mohamed, et al.. (2011). Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. European Journal of Pharmacology. 659(2-3). 289–295. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Onkar Bedi Breakdown of academic impact, for papers by Mohamed N. Amin Breakdown of academic impact, for papers by Afagh Garjani Breakdown of academic impact, for papers by Shukui Wang Breakdown of academic impact, for papers by Hongwei Shi Breakdown of academic impact, for papers by Michel Guillaume Breakdown of academic impact, for papers by Neelam Malik Breakdown of academic impact, for papers by Qianzhou Lv Breakdown of academic impact, for papers by Sanlan Wu Breakdown of academic impact, for papers by Xiaoxia Qiu
Rankless by CCL
2026